Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744132 | 0.84 | ALDH1A1 (0.41) | L3MBTL1BACE1DUTTSHR | |
| SCHEMBL28516262 | 0.80 | MAPK1 (0.40) | MTNR1AKDM4EL3MBTL1TSHR | |
| SCHEMBL15941254 | 0.80 | BACE1 (0.32) | BACE1DUT | |
| SCHEMBL26121759 | 0.79 | MCL1 (0.50) | KDM4E | |
| SCHEMBL15863147 | 0.79 | POLB (0.37) | KDM4EBACE1DUT | |
| SCHEMBL14498357 | 0.78 | GAA (0.41) | L3MBTL1TSHR | |
| SCHEMBL20163331 | 0.76 | BACE1 (0.32) | GLABACE1 | |
| SCHEMBL20363234 | 0.76 | KMT2A (0.41) | MTNR1ABACE1DUTTSHR | |
| SCHEMBL1143295 | 0.76 | TDP1 (0.49) | — | |
| SCHEMBL31271525 | 0.76 | BACE1 (0.30) | BACE1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120996-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2016-05-05 | — | — | US | disclosed |
| EP-1888082-B1 | MOTILIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7582611-B2 | Treating disorders of gastric motility; decreasing side effects of erythromycin A | PFIZER INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1888082-A4 | MOTILIDE COMPOUNDS | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1888082-A1 | MOTILIDE COMPOUNDS | Pfizer, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127252-A1 | MOTILIDE COMPOUNDS | PFIZER, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270616-A1 | Motilide compounds | PFIZER INC. | 2006-11-30 | — | — | US | disclosed |
| EP-0838465-A1 | Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics | F. HOFFMANN-LA ROCHE AG (CH) | 1998-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270616-A1 | Motilide compounds | MLNR, PROKR1, GIPR | MTNR1A 17/4885KDM4E 4388/4885GLA 2623/4885 |
| US-20160120996-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, LNPK, MBOAT1 | MTNR1A 982/4885KDM4E 4823/4885GLA 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.